Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis

Minoru Nakamura; Atsumasa Komori; Masahiro Ito; Hisayoshi Kondo; Yoshihiro Aiba; Kiyoshi Migita; Shinya Nagaoka; Kazuyuki Ohata; Koji Yano; Seigo Abiru; Manabu Daikoku; Hiroshi Yatsuhashi; Shinji Shimoda; Hiromi Ishibashi

doi:10.1111/j.1872-034X.2007.00244.x

Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis

Minoru Nakamura, Atsumasa Komori, Masahiro Ito, Hisayoshi Kondo, Yoshihiro Aiba, Kiyoshi Migita, Shinya Nagaoka, Kazuyuki Ohata, Koji Yano, Seigo Abiru, Manabu Daikoku, Hiroshi Yatsuhashi, Shinji Shimoda, Hiromi Ishibashi

Department of Clinical Immunology and Rheumatology / Infectious Disease

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

Because some of the autoreactive T-cell clones specific for human PDC-E2 cross-react to mimicry peptides having an EIExDK motif derived from nuclear antigens such as human gp210 and sp100, we studied the clinical significance of antinuclear antibodies (ANA) in primary biliary cirrhosis (PBC) patients registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). We found that there are two different types of progression in PBC; one is a hepatic failure-type progression which is represented by positive anti-gp210 antibodies and the other is a portalhypertension-type progression which is represented by positive anticentromere antibodies. We discuss the predictive role of these ANA in the long-term outcome of PBC and the mechanisms by which two different PBC progression types occur based on molecular mimicry and aberrant expression of nuclear antigens.

Original language	English
Pages (from-to)	S412-S419
Journal	Hepatology Research
Volume	37
Issue number	SUPPL. 3
DOIs	https://doi.org/10.1111/j.1872-034X.2007.00244.x
Publication status	Published - Oct 2007

All Science Journal Classification (ASJC) codes

Hepatology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1872-034X.2007.00244.x

Cite this

Nakamura, M., Komori, A., Ito, M., Kondo, H., Aiba, Y., Migita, K., Nagaoka, S., Ohata, K., Yano, K., Abiru, S., Daikoku, M., Yatsuhashi, H., Shimoda, S., & Ishibashi, H. (2007). Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatology Research, 37(SUPPL. 3), S412-S419. https://doi.org/10.1111/j.1872-034X.2007.00244.x

Nakamura, M, Komori, A, Ito, M, Kondo, H, Aiba, Y, Migita, K, Nagaoka, S, Ohata, K, Yano, K, Abiru, S, Daikoku, M, Yatsuhashi, H, Shimoda, S & Ishibashi, H 2007, 'Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis', Hepatology Research, vol. 37, no. SUPPL. 3, pp. S412-S419. https://doi.org/10.1111/j.1872-034X.2007.00244.x

@article{f54f1b6cd0ba429c879ad16237b65e1b,

title = "Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis",

abstract = "Because some of the autoreactive T-cell clones specific for human PDC-E2 cross-react to mimicry peptides having an EIExDK motif derived from nuclear antigens such as human gp210 and sp100, we studied the clinical significance of antinuclear antibodies (ANA) in primary biliary cirrhosis (PBC) patients registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). We found that there are two different types of progression in PBC; one is a hepatic failure-type progression which is represented by positive anti-gp210 antibodies and the other is a portalhypertension-type progression which is represented by positive anticentromere antibodies. We discuss the predictive role of these ANA in the long-term outcome of PBC and the mechanisms by which two different PBC progression types occur based on molecular mimicry and aberrant expression of nuclear antigens.",

author = "Minoru Nakamura and Atsumasa Komori and Masahiro Ito and Hisayoshi Kondo and Yoshihiro Aiba and Kiyoshi Migita and Shinya Nagaoka and Kazuyuki Ohata and Koji Yano and Seigo Abiru and Manabu Daikoku and Hiroshi Yatsuhashi and Shinji Shimoda and Hiromi Ishibashi",

year = "2007",

month = oct,

doi = "10.1111/j.1872-034X.2007.00244.x",

language = "English",

volume = "37",

pages = "S412--S419",

journal = "Hepatology Research",

issn = "1386-6346",

publisher = "Wiley-Blackwell",

number = "SUPPL. 3",

}

TY - JOUR

T1 - Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis

AU - Nakamura, Minoru

AU - Komori, Atsumasa

AU - Ito, Masahiro

AU - Kondo, Hisayoshi

AU - Aiba, Yoshihiro

AU - Migita, Kiyoshi

AU - Nagaoka, Shinya

AU - Ohata, Kazuyuki

AU - Yano, Koji

AU - Abiru, Seigo

AU - Daikoku, Manabu

AU - Yatsuhashi, Hiroshi

AU - Shimoda, Shinji

AU - Ishibashi, Hiromi

PY - 2007/10

Y1 - 2007/10

N2 - Because some of the autoreactive T-cell clones specific for human PDC-E2 cross-react to mimicry peptides having an EIExDK motif derived from nuclear antigens such as human gp210 and sp100, we studied the clinical significance of antinuclear antibodies (ANA) in primary biliary cirrhosis (PBC) patients registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). We found that there are two different types of progression in PBC; one is a hepatic failure-type progression which is represented by positive anti-gp210 antibodies and the other is a portalhypertension-type progression which is represented by positive anticentromere antibodies. We discuss the predictive role of these ANA in the long-term outcome of PBC and the mechanisms by which two different PBC progression types occur based on molecular mimicry and aberrant expression of nuclear antigens.

AB - Because some of the autoreactive T-cell clones specific for human PDC-E2 cross-react to mimicry peptides having an EIExDK motif derived from nuclear antigens such as human gp210 and sp100, we studied the clinical significance of antinuclear antibodies (ANA) in primary biliary cirrhosis (PBC) patients registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). We found that there are two different types of progression in PBC; one is a hepatic failure-type progression which is represented by positive anti-gp210 antibodies and the other is a portalhypertension-type progression which is represented by positive anticentromere antibodies. We discuss the predictive role of these ANA in the long-term outcome of PBC and the mechanisms by which two different PBC progression types occur based on molecular mimicry and aberrant expression of nuclear antigens.

UR - http://www.scopus.com/inward/record.url?scp=35348899452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348899452&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2007.00244.x

DO - 10.1111/j.1872-034X.2007.00244.x

M3 - Article

C2 - 17931196

AN - SCOPUS:35348899452

SN - 1386-6346

VL - 37

SP - S412-S419

JO - Hepatology Research

JF - Hepatology Research

IS - SUPPL. 3

ER -

Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this